Evaluation of the proper dosage of lapatinib and its safety in dogs
Lapatinib is a low-molecular-weight agent targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It is one of the antitumor agents used against advanced breast cancer in human. We intended to apply it against canine mammary gland tumors (cMGTs). To...
Main Authors: | Tanaka, Yuiko, Watanabe, Manabu, Saeki, Kohei, Ong, Siew Mei, Yoshitake, Ryohei, Imamura, Shohei, Nishimura, Ryohei, Sugano, Sumio, Nakagawa, Takayuki |
---|---|
Format: | Article |
Language: | English |
Published: |
Tokyo Metropolitan Institute of Medical Science
2020
|
Online Access: | http://psasir.upm.edu.my/id/eprint/88878/1/DOG.pdf |
Similar Items
-
Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
by: Shotaro Eto, et al.
Published: (2019-01-01) -
Single-Cell Transcriptomics Identifies Heterogeneity of Mouse Mammary Gland Fibroblasts With Distinct Functions, Estrogen Responses, Differentiation Processes, and Crosstalks With Epithelium
by: Ryohei Yoshitake, et al.
Published: (2022-03-01) -
Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
by: Shingo Maeda, et al.
Published: (2022-01-01) -
Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma
by: Satoshi Kamoto, et al.
Published: (2020-11-01) -
Thiamylal sodium increased inflammation and the proliferation of vascular smooth muscle cells
by: Ryohei Miyazaki, et al.
Published: (2016-06-01)